Why do Smart Cells choose to use Sepax TM processing methodology?
Smart Cells International (SCI) has chosen to use Sepax TM to process cord blood as this technology is an industry leader in the field and is trusted worldwide in the field of stem cell banking.
The Sepax TM platform allows closed system processing that is sterile, accurate and produces a final product that works with recognised cryopreservation and long term storage techniques. Furthermore, the Sepax TM product is produced in a format that allows easy testing if required and is compatible with end-user transplant requirements in hospitals.
We undertake regular auditing of cord blood yields following processing and again after freezing and thawing processed cells. It is well recognised clinically that both the Total Nucleated Cell Count (TNC) and viable CD34+ stem cell doses in a cord blood unit following thawing for use are critical to successful clinical outcome. Our testing data is summarised in the chart below.
Many thousands of patients have been satisfactorily transplanted worldwide using cord blood units processed using Sepax TM or the other main industry leader, AXP (1). Respected establishments quote levels of viable CD34 stem cell post-thaw recovery with >70% being an accepted average for clinical use (2). In mainstream stem cell transplantation to treat patients with cancers of the blood and bone marrow, for example, high numbers of stem cells are required to restore the bone marrow function which is typically damaged by chemotherapy used as part of the treatment regime. In regenerative medicine, cell doses are less well determined and fewer cells may be required but SCI are aware from working with the Duke University Hospital Translational Medicine Unit that their team set an optimal viable post-thaw CD34 stem cell level at 70%.
We, along with other respected stem cell banks trust the Sepax TM system to deliver high-quality cord blood stem cell yields efficiently.